Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

34.17USD
23 Jun 2017
Change (% chg)

$0.11 (+0.32%)
Prev Close
$34.06
Open
$34.06
Day's High
$34.22
Day's Low
$33.97
Volume
12,866,271
Avg. Vol
6,530,470
52-wk High
$37.39
52-wk Low
$29.83

Latest Key Developments (Source: Significant Developments)

FDA says fagron sterile services issues voluntary nationwide recall of succinylcholine chloride
Friday, 23 Jun 2017 04:27pm EDT 

June 23 (Reuters) - Pfizer Inc ::FDA says fagron sterile services issues voluntary nationwide recall of succinylcholine chloride due to potential for lack of sterility assurance.FDA - recall of product manufactured by Hospira Inc is due to microbial growth detected during routine simulation of Hospira's manufacturing process.FDA - to date, there have been no reports of adverse events related to the succinylcholine chloride 20mg/ml 5ml syringe product.  Full Article

Pfizer sets quarterly dividend of $0.32 per share
Thursday, 22 Jun 2017 04:05pm EDT 

June 22 (Reuters) - Pfizer -:Pfizer declares 32-cent third-quarter 2017 dividend.Sets quarterly dividend of $0.32 per share.  Full Article

Pfizer receives Health Canada approval for Ibrance in hr+, her2- metastatic breast cancer
Wednesday, 21 Jun 2017 08:00am EDT 

June 21 (Reuters) - Pfizer Inc :Pfizer receives expanded Health Canada approval for ibrance in hr+, her2- metastatic breast cancer.  Full Article

Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer
Tuesday, 20 Jun 2017 08:00am EDT 

June 20 (Reuters) - Merck Kgaa :Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer.Effector Therapeutics - cos plan to initiate Phase 2 study to evaluate EFT508 in combination with avelumab in microsatellite stable relapsed or refractory CRC patients.Effector Therapeutics - Pfizer and Merck KGAA will share clinical study costs with effector.  Full Article

Pfizer begins Phase 1 clinical trial to evaluate investigational Group B streptococcus vaccine
Monday, 19 Jun 2017 08:00am EDT 

June 19 (Reuters) - Pfizer Inc :Pfizer begins Phase 1 clinical trial to evaluate investigational Group B streptococcus vaccine.Pfizer Inc - trial will be conducted in United States.  Full Article

U.S. FDA updates on Pfizer drug shortages
Thursday, 15 Jun 2017 06:32pm EDT 

June 15 (Reuters) - U.S. FDA ::Says it is aware of the ongoing shortage situation affecting several injectable drugs, manufactured by Hospira, a Pfizer company.Says Pfizer has reported the shortage is caused by manufacturing, distribution and third party delays.Says it is working closely with Pfizer to resolve critical shortages by addressing underlying causes.Says working to relieve these shortages through a variety of measures, including finding alternative manufacturers of these drug products.Says continues to explore all available options to relieve shortages, which may include expediting review of applications or other submissions.Says it may also consider temporary regulatory flexibility for alternative sources to relieve shortages as it continues to explore options.Says shortage affecting injectable drugs, including sodium bicarbonate injection (vials & syringes), dextrose 50% injection (vials & syringes).Says shortage also affecting emergency syringes of drugs, including epinephrine, calcium chloride and atropine sulfate.  Full Article

Pfizer and Lilly receive FDA fast track designation for Tanezumab
Tuesday, 13 Jun 2017 08:00am EDT 

June 13 (Reuters) - Pfizer Inc :Pfizer and Lilly receive FDA fast track designation for Tanezumab.‍Phase 3 global clinical development program for Tanezumab is currently ongoing.‍Results are projected to begin reporting out in 2018​.  Full Article

Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy
Wednesday, 7 Jun 2017 07:30am EDT 

June 7 (Reuters) - Sangamo Therapeutics::Sangamo Therapeutics and Pfizer announce that SB-525 investigational hemophilia A gene therapy receives orphan medicinal product designation from the European medicines agency.Cos also announce Phase 1/2 clinical trial evaluating SB-525 in adults with severe hemophilia A is now open for enrollment.Sangamo Therapeutics Inc - initial data from study of SB-525 in adults with hemophilia A expected in late 2017 or early 2018.  Full Article

Pfizer receives FDA fast track designation for Tafamidis for transthyretin cardiomyopathy
Tuesday, 6 Jun 2017 08:00am EDT 

June 6 (Reuters) - Pfizer Inc :Pfizer receives FDA fast track designation for tafamidis for transthyretin cardiomyopathy.Pfizer Inc - ‍Tafamidis, an investigational medicine for ttr-cm, is currently in phase 3 development​.Pfizer Inc - ‍attr-act study is fully enrolled and is anticipated to be completed in first half of 2018​.  Full Article

Pfizer defeats appeal over Zoloft
Friday, 2 Jun 2017 08:48am EDT 

June 2 (Reuters) - u.s. Appeals court upholds dismissal of lawsuits against pfizer claiming that its antidepressant zoloft causes birth defects--ruling:.  Full Article

More From Around the Web

Photo

Novartis breast cancer drug Kisqali wins European panel backing

ZURICH A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.